Significance of RB Loss in Unlocking Phenotypic Plasticity in Advanced Cancers

• Published in: Molecular cancer research Vol. 21; no. 6; pp. 497 - 510
• Main Authors: Venkadakrishnan, Varadha Balaji, Yamada, Yasutaka, Weng, Kenny, Idahor, Osasenaga, Beltran, Himisha
• Format: Journal Article
• Language: English
• Published: United States 01.06.2023
• Subjects: Humans; Neoplasms - genetics
• ISSN: 1541-7786; 1557-3125
• DOI: 10.1158/1541-7786.MCR-23-0045

Cancer cells can undergo plasticity in response to environmental stimuli or under selective therapeutic pressures that result in changes in phenotype. This complex phenomenon of phenotypic plasticity is now recognized as a hallmark of cancer. Lineage plasticity is often associated with loss of dependence on the original oncogenic driver and is facilitated, in part, by underlying genomic and epigenetic alterations. Understanding the molecular drivers of cancer plasticity is critical for the development of novel therapeutic strategies. The retinoblastoma gene RB1 (encoding RB) is the first tumor suppressor gene to be discovered and has a well-described role in cell-cycle regulation. RB is also involved in diverse cellular functions beyond cell cycle including differentiation. Here, we describe the emerging role of RB loss in unlocking cancer phenotypic plasticity and driving therapy resistance across cancer types. We highlight parallels in cancer with the noncanonical role of RB that is critical for normal development and lineage specification, and the downstream consequences of RB loss including epigenetic reprogramming and chromatin reorganization that can lead to changes in lineage program. Finally, we discuss potential therapeutic approaches geared toward RB loss cancers undergoing lineage reprogramming.